Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov ID: NCT00664105

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00664105. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

PhII Study of Concurrent Chemoradiotherapy With Weekly Docetaxel, Carboplatin and Radiation Therapy Followed by Consolidation Chemotherapy With Docetaxel and Carboplatin for Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Because of its success in advanced NSCLC both as a single agent and in combination with other chemotherapeutics, it is reasonable to investigate the efficacy and toxicity of docetaxel as a multimodality regimen in this patient population. Docetaxel at a dose of 20 mg/m2 appears to be a well-tolerated "weekly" dose when combined with either cisplatin 25 mg/m2 20-22 or carboplatin area under the curve (AUC) 2 23-25 concomitant with radiation therapy. PURPOSE: To explore the potential benefits of the radiosensitizing effects of weekly docetaxel/carboplatin/radio therapy concurrent therapy followed full dose systemic docetaxel/carboplatin consolidation therapy on overall response rate, survival, progression-free survival, safety and toxicity in patients with locally advanced NSCLC.

Study identification

NCT ID
NCT00664105
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Enrollment
63 participants

Conditions and interventions

Conditions

Interventions

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 2004 (Type not available)
Primary completion
Jun 2008 (Actual)
Completion
Jun 2008 (Actual)
Last update posted
Sep 7, 2012

2004 – 2008

United States locations

U.S. sites
15
U.S. states
7
U.S. cities
12
Facility City State ZIP Site status
M.D. Anderson Cancer Center, Orlando Orlando Florida 32806 —
Chesapeake Oncology Hematology Associates Baltimore Maryland 21225 —
University Hospital of Cleveland Cleveland Ohio 44106 —
Lehigh Valley Hospital - John & Dorothy Morgan Cancer Center Allentown Pennsylvania 18103 —
Erlanger Health System Chattanooga Tennessee 37403 —
Clarksville Regional Hematology Oncology Group Clarksville Tennessee 37043 —
Jackson Madison County Hospital Jackson Tennessee 38301 —
Tennessee Cancer Specialists Knoxville Tennessee 37920 —
University of Tennessee Medical Center Knoxville Tennessee 37920 —
The West Clinic, PC Memphis Tennessee 38120 —
St. Thomas Health Services Nashville Tennessee 37205 —
Meharry Medical College Nashville Tennessee 37208 —
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232 —
UT Southwestern Medical Center Dallas Texas 75390 —
Swedish Cancer Institute Seattle Washington 98104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00664105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 7, 2012 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.